The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials

The introduction of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the management of heart failure with preserved ejection fraction (HFpEF) may be regarded as the first effective treatment in these patients. However, this proposition must be evaluated from the perspective of the complexity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Luxi, Mishra, Mudit, De Geest, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140883/
https://www.ncbi.nlm.nih.gov/pubmed/37111578
http://dx.doi.org/10.3390/pharmaceutics15041092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140883/
https://www.ncbi.nlm.nih.gov/pubmed/37111578
http://dx.doi.org/10.3390/pharmaceutics15041092

Ejemplares similares